Announcement PDF RADIOPHARM THERANOSTICS EGM PRESENTATION 18 August 2023 IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. R A DIO P H A R M TH E R A N O STIC S L TD 20 23 2 RAD accomplishments over the past 12 months Pivalate Positive Phase 2a data in Brain Mets study October 2022 Trivehexin (Integrin) FDA IND approval received for Phase 1 in pancreatic cancer December 2022 Trivehexin (Integrin) Orphan Drug status granted for by FDA May 2023 Nanomab HER2 Positive pre-IND (Type A) meeting with FDA February 2023 MD Anderson Joint Ventures R&D agreement signed with one of the leading cancer centre globally November 2022 Isotope Supply Chain secured with multiple global contracts for Lu177, Ac225 and Tb 161 Over 2022 and 2023 3 On the cusp of clinical data Program T/D1 Pivalate Dx Q3 CY23: FDA IND approval a small Phase 2b trial with potential to lead into a Phase 3 trial shortly after Patients: 30 Finish*: Q2 CY24 Trivehexin (Integrin) Dx Q3 CY23: Dosing of first patient in Phase 1 imaging trial in pancreatic cancer at Albert Einstein Centre in New York Q4 CY23: Phase 1 data release & preparation for Phase 2 Q2 CY24: Dose first patient in Phase 2 trial Patients: 9 Finish*: CY23 Nanomab PDL1 Tx Q3 CY23: Australian Ethics approval for the Phase 1 therapeutic study in lung cancer and dose first patient Patients: 27 Finish*: Q1 CY25 Tx Q4 CY23: FDA IND approval for Phase 1 therapeutic in breast and gastric cancers and dose first patient. Patients: 21 Finish*: Q1 CY25 Nanomab HER2 Development Timing Details * Time based on patient availability and recruitment rate CY23: 2 Dx trial read-outs, 2 Tx trials started 1. Dx = diagnostic, Tx = therapeutic 4 Shareholder value creation late CY23 and into CY24  Shareholder value is created when drugs are de-risked, we are focused on the “big changes in value”    Moving into late stage human trials before commercialisation Transferring the drug from animal models to human trials Board is focused on programs to create shareholder value while maintaining tight capital controls     Phase 2b Pivalate: Phase 1 Trivehexin: Phase 1 NanoMab PDL1: Phase 1 NanoMab HER2: Diagnostic in Brain Metastases (read out Q2 CY2024) Diagnostic in Pancreatic Cancer (read out end of 2023) Therapeutic in Lung Cancer (read out Q1 of CY2025) Therapeutic in Breast and gastric Cancer (read out Q1 of CY2025)  Management of company with limited overheads by keeping only essential staff on payroll. Only eleven science & clinical specialists managing four logistically intensive clinical programs in two countries.  We have no office overhead, no admin staff, overall very low SG&A1. 1. SG&A = selling, general and administrative expenses 5 Significant Company transformation anticipated from preclinical to clinical stage with 3 FDA IND trials in USA & 1 CTN/Ethics trial in Australia 6 CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited T +1 862 309 0293 Radiopharm Theranostics Limited T +61 406 671 515 E E rc@radiopharmtheranostic.com W www.radiopharmtheranostics.com R A DIO P H A R M TH E R A N O STIC S L TD 20 21 paulhopper@lifescienceportfolio.com W www.radiopharmtheranostics.com C O N FIDE N TIA L | 7